Nurix Therapeutics price target raised to $17 from $16 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Nurix Therapeutics (NRIX) to $17 from $16 and keeps an Equal Weight rating on the shares. The firm, which refreshed its model for Q4 results, notes that multiple clinical updates are anticipated across the pipeline in 2025 and contends that NX-5948 “remains the key driver for the stock.”